[Research Report] The patient-derived xenograft model market size is projected to grow from US$ 378.46 million in 2022 to US$ 975.31 million by 2030; it is estimated to record a CAGR of 12.6% during 2022–2030.
Market Insights and Analyst View:
The patient-derived xenograft (PDX) model refers to laboratory models that are created by implanting patient tumor tissues directly into immunodeficient mice. These models are used in preclinical research to study the behavior of tumors and evaluate the efficacy of potential therapies. The market is expected to exhibit a promising performance over the next decade. Driven by elevating investments in cancer research and rising demand for personalized medicine, the adoption of PDX models is likely to surge significantly. As drug developers strive to improve their clinical success rates, PDX models are becoming a valuable tool due to their ability to mimic human tumor behavior and suitability for therapy response prediction studies, which favor the growth of the patient-derived xenograft model market
Growth Drivers:
Mice that are immunocompromised are now reconstituted with bone marrow or peripheral blood cells and patients’ tumor implants to create humanized xenograft models. Humanized models can be utilized to study the role of xenogeneic immune cells in overall anti-cancer immunity. Humanized models also help in the development of immunotherapy drugs. However, in humanized mice models, there is a risk of graft vs. host disease, which may hamper the outcomes of stroma-tumor interaction evaluation studies. These interactions are essential for tumor growth and progression in patients. Humanized models engrafted with PDX offer a promising approach to oncology research, providing an improved understanding of human tumors and accelerating the development of personalized treatments. PDX models offer numerous advantages, including the depiction of the patient’s tumor microenvironment and its diversity, the detection of therapeutic targets, the determination of the potential for developing personalized therapies, and the interaction with a complete human immune system. Humanized patient-derived xenograft models help overcome the humanized mice models' drawbacks and are gaining demand in the market. For example, Champions Oncology has developed more than 1,500 diverse tumor models from various patients in the primary or metastatic phase. Thus, the growing awareness regarding the benefits of humanized PDX models boosts the patient-derived xenograft model market growth during the forecast period.
Moreover, the patient-derived xenograft model market trends include the development of next-generation PDX technologies and ongoing research studies for drug development.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Patient-Derived Xenograft Model Market: Strategic Insights
Market Size Value in US$ 378.46 million in 2022 Market Size Value by US$ 975.31 million by 2030 Growth rate CAGR of 12.6% from 2022 to 2030 Forecast Period 2022-2030 Base Year 2022
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Patient-Derived Xenograft Model Market: Strategic Insights
| Market Size Value in | US$ 378.46 million in 2022 |
| Market Size Value by | US$ 975.31 million by 2030 |
| Growth rate | CAGR of 12.6% from 2022 to 2030 |
| Forecast Period | 2022-2030 |
| Base Year | 2022 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Report Segmentation and Scope:
The patient-derived xenograft model market analysis has been carried out by considering the following segments: model type, tumor type, application, end user, and geography. Based on model type, the market is categorized into mice models and rats models. In terms of tumor type, the patient-derived xenograft model market is classified into gastrointestinal tumor models, gynecological tumor models, respiratory tumor models, and other tumor models. The market, by application, is segmented into preclinical drug development, biomarker analysis, translational research, and biobanking. Based on end user, the market is segmented into pharmaceutical and biotechnology companies, academic and government research institutions, and contract research organizations.
The scope of the patient-derived xenograft model market report covers North America (US, Canada, and Mexico), Europe (France, Germany, UK, Spain, Italy, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, UAE, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).
Segmental Analysis:
The patient-derived xenograft model market, by model type, is bifurcated into mice models and rats models. The mice models segment held a significant market share in 2022. It is anticipated to record a higher CAGR in the market during 2022–2030.
Based on tumor type, the market is segmented into gastrointestinal tumor models, respiratory tumor models, gynecological tumor models, and other tumor models. In 2022, the other tumor model segment held a significant share of the market and is projected to register the fastest CAGR during 2022–2030.
Based on application, the market is categorized into preclinical drug development, biomarker analysis, translational research, and biobanking. The preclinical drug development segment held a significant patient-derived xenograft model market share in 2022. The segment is estimated to register the highest CAGR during 2022–2030.
Based on end user, the market is segmented into pharmaceutical and biotechnology companies, contract research organizations, and academic and government research institutions. The academic and government research institutions segment held a significant patient-derived xenograft model market share in 2022. It is expected to register the highest CAGR during 2022–2030.
Regional Analysis:
Based on geography, the patient-derived xenograft model market report is primarily divided into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2022, North America captured a significant share of the market. In 2022, the US held the largest share of the market in the region. The market growth in North America is attributed to the availability of modern healthcare infrastructure, the strong presence of key market players, the growing number of cancer cases, and rising investments by the government and private sectors. As per the Centers for Disease Control and Prevention, in 2020, ~239,612 new cases of breast cancer were reported among women in the US, while ~42,273 succumbed to death due to this disease. For every 100,000 women, 119 new breast cancer cases were reported in women, of which nearly 19 have died. As per the breast cancer statistics by the Breast Cancer Organization, about 1 in 8 women (i.e., 12%) develops invasive breast cancer in their lifetime. Moreover, as breast cancer is the most prevalent cancer in Canadian women and the second leading reason for cancer deaths, there is a high demand for efficient diagnosis options. According to the Canadian Cancer Society, ~28,600 women were diagnosed with breast cancer in 2022 in the country, accounting for ~25% of the total new cancer cases in women. With growing cancer cases, the need to develop suitable treatment arises, which propels the growth of the patient-derived xenograft model market.
According to an article published in April 2022 by Oncoimmunology, researchers used the diversity outbred (DO) and collaborative cross (CC) mouse models to study the outcomes of the immune checkpoint inhibitors against various tumors. For this study, the researchers purchased the DO mice models from the Jackson Laboratory and CC mice from the Systems Genetics Core Facility at the University of North Carolina. Thus, the growing research and the use of mouse models for anticancer drug discovery propels the patient-derived xenograft model market growth in the region.
Patient-Derived Xenograft Model Market Report Scope
Industry Developments and Future Opportunities:
Initiatives taken by market players operating in the global patient-derived xenograft model market are listed below:
- In July 2022, GemPharmatech entered a strategic licensing arrangement with Charles River Laboratories. The partnership involves the exclusive distribution rights for GemPharmatech's next-generation NOD CRISPR Prkdc Il2r gamma (NCG) mice lines within North America.
- In November 2021, Inotiv Inc. completed the acquisition of Envigo RMS Holding Corp., a globally leading provider of research models and services.
Competitive Landscape and Key Companies:
The patient-derived xenograft model market forecast can help stakeholders plan their growth strategies. Champions Oncology Inc., Charles River Laboratories Inc., Crown Bioscience Inc., EPO Berlin-Buch GmbH, Hera BioLabs, Horizon Discovery Group plc, Oncodesign, Pharmatest Services Ltd, Xentech SAS, and JSR Corporation are among the prominent players in the market. The market players focus on introducing new high-tech products, advancements in existing products, and geographic expansions to meet the growing consumer demand worldwide.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Model Type, Tumor Type, Application, End User, and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The factors driving the growth of the patient-derived xenograft model market include the growing awareness of the advantages of humanized PDX models and the rising demand for personalized medicine. However, significant operational costs associated with the PDX model hampers the growth of the patient-derived xenograft model market.
The patient-derived xenograft (PDX) model refers to laboratory models that are created by implanting patient tumor tissues directly into immunodeficient mice. These models are used in preclinical research to study the behavior of tumors and evaluate the efficacy of potential therapies.
The global patient-derived xenograft model market is segmented based on model type, tumor type, application, and end user. The patient-derived xenograft model market, by model type, is categorized into mice models and rats models. The mice models segment held a significant share of the market in 2022 and is expected to register a higher CAGR in the market during 2022–2030.
The patient-derived xenograft model market was valued at US$ 378.46 million in 2022.
The patient-derived xenograft model market is expected to be valued at US$ 975.31 million in 2030.
The patient-derived xenograft model market majorly consists of the players, including Champions Oncology Inc., Charles River Laboratories Inc., Crown Bioscience Inc., EPO Berlin-Buch GmbH, Hera BioLabs, Horizon Discovery Group plc, Oncodesign, Pharmatest Services Ltd, Xentech SAS, and JSR Corporation.
1. Introduction
1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness Analysis
3. Research Methodology
4. Patient-Derived Xenograft Models Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
4.3.1 List of Vendors in the Value Chain
5. Patient-Derived Xenograft Models Market - Key Market Dynamics
5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints
6. Patient-Derived Xenograft Models Market - Global Market Analysis
6.1 Patient-Derived Xenograft Models - Global Market Overview
6.2 Patient-Derived Xenograft Models - Global Market and Forecast to 2030
7. Patient-Derived Xenograft Models Market – Revenue Analysis (USD Million) – By Type, 2020-2030
7.1 Overview
7.2 Mice Model
7.3 Rats Model
8. Patient-Derived Xenograft Models Market – Revenue Analysis (USD Million) – By Tumor Type, 2020-2030
8.1 Overview
8.2 Gastrointestinal Tumor Model
8.3 Gynecological Tumor Model
8.4 Respiratory Tumor Model
8.5 Other Tumor Model
9. Patient-Derived Xenograft Models Market – Revenue Analysis (USD Million) – By Application, 2020-2030
9.1 Overview
9.2 Preclinical Drug Development
9.3 Biomarker Analysis
9.4 Translational Research
9.5 Biobanking
10. Patient-Derived Xenograft Models Market – Revenue Analysis (USD Million) – By End Users, 2020-2030
10.1 Overview
10.2 Pharmaceutical and Biotechnology Companies
10.3 Academic and Government Research Institutions
10.4 Contract Research Organizations
11. Patient-Derived Xenograft Models Market - Revenue Analysis (USD Million), 2020-2030 – Geographical Analysis
11.1 North America
11.1.1 North America Patient-Derived Xenograft Models Market Overview
11.1.2 North America Patient-Derived Xenograft Models Market Revenue and Forecasts to 2030
11.1.3 North America Patient-Derived Xenograft Models Market Revenue and Forecasts and Analysis - By Type
11.1.4 North America Patient-Derived Xenograft Models Market Revenue and Forecasts and Analysis - By Tumor Type
11.1.5 North America Patient-Derived Xenograft Models Market Revenue and Forecasts and Analysis - By Application
11.1.6 North America Patient-Derived Xenograft Models Market Revenue and Forecasts and Analysis - By End Users
11.1.7 North America Patient-Derived Xenograft Models Market Revenue and Forecasts and Analysis - By Countries
11.1.7.1 United States Patient-Derived Xenograft Models Market
11.1.7.1.1 United States Patient-Derived Xenograft Models Market, by Type
11.1.7.1.2 United States Patient-Derived Xenograft Models Market, by Tumor Type
11.1.7.1.3 United States Patient-Derived Xenograft Models Market, by Application
11.1.7.1.4 United States Patient-Derived Xenograft Models Market, by End Users
11.1.7.2 Canada Patient-Derived Xenograft Models Market
11.1.7.2.1 Canada Patient-Derived Xenograft Models Market, by Type
11.1.7.2.2 Canada Patient-Derived Xenograft Models Market, by Tumor Type
11.1.7.2.3 Canada Patient-Derived Xenograft Models Market, by Application
11.1.7.2.4 Canada Patient-Derived Xenograft Models Market, by End Users
11.1.7.3 Mexico Patient-Derived Xenograft Models Market
11.1.7.3.1 Mexico Patient-Derived Xenograft Models Market, by Type
11.1.7.3.2 Mexico Patient-Derived Xenograft Models Market, by Tumor Type
11.1.7.3.3 Mexico Patient-Derived Xenograft Models Market, by Application
11.1.7.3.4 Mexico Patient-Derived Xenograft Models Market, by End Users
Note - Similar analysis would be provided for below mentioned regions/countries
11.2 Europe
11.2.1 Germany
11.2.2 France
11.2.3 Italy
11.2.4 Spain
11.2.5 United Kingdom
11.2.6 Rest of Europe
11.3 Asia-Pacific
11.3.1 Australia
11.3.2 China
11.3.3 India
11.3.4 Japan
11.3.5 South Korea
11.3.6 Rest of Asia-Pacific
11.4 Middle East and Africa
11.4.1 South Africa
11.4.2 Saudi Arabia
11.4.3 U.A.E
11.4.4 Rest of Middle East and Africa
11.5 South and Central America
11.5.1 Brazil
11.5.2 Argentina
11.5.3 Rest of South and Central America
12. Industry Landscape
12.1 Mergers and Acquisitions
12.2 Agreements, Collaborations, Joint Ventures
12.3 New Product Launches
12.4 Expansions and Other Strategic Developments
13. Competitive Landscape
13.1 Heat Map Analysis by Key Players
13.2 Company Positioning and Concentration
14. Patient-Derived Xenograft Models Market - Key Company Profiles
14.1 Champions Oncology, Inc.
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
Note - Similar information would be provided for below list of companies
14.2 Charles River Laboratories, Inc.
14.3 Crown Bioscience, Inc.
14.4 EPO Berlin-Buch GmbH
14.5 Hera BioLabs
14.6 Horizon Discovery Group plc
14.7 Oncodesign
14.8 Pharmatest Services Ltd
14.9 Xentech SAS
14.10 JSR Corporation
15. Appendix
15.1 Glossary
15.2 About The Insight Partners
15.3 Market Intelligence Cloud
The List of Companies - Patient-Derived Xenograft Model Market
- Champions Oncology Inc.
- Charles River Laboratories Inc.
- Crown Bioscience Inc.
- EPO Berlin-Buch GmbH
- Hera BioLabs
- Horizon Discovery Group plc
- Oncodesign
- Pharmatest Services Ltd
- Xentech SAS
- JSR Corporation.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Patient-Derived Xenograft Model Market
Feb 2024
Mobile Cleanroom Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Softwall and Hardwall), End User (Microelectronics Industry, Pharmaceuticals and Biotechnology Industry, Medical Device Manufacturers, and Others), and Geography
Feb 2024
Ovo-Sexing Technology Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Technique (Non-Invasive Imaging, Genetic Editing, Volatile Analysis, Sex Reversal, and Liquid-Based Analysis), End User (Hatcheries and Poultry Farms), and Geography (US, Germany, France, Italy, Spain, Rest of Europe, Israel, and ROW)
Feb 2024
Dental Laser Treatment Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Application (Hard Tissue, Soft Tissue, and Others), End User (Hospitals, Dental Clinics, Dental-Owned Practices, and Others), Clinical Indication [Conservative Dentistry, Root Canal (Endodontic Treatment), Oral Surgery, Implantology, Peri-Implantitis, Periodontics, and Others], and Geography
Feb 2024
Microbiology CRO Services Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Application (Clinical, Medical Device, and Others), Service Type (Assay Development, Custom Viral Stock Production, Microbial Testing, and Others), Microorganisms (Bacteria, Fungi, Viruses, and Parasites), End User (Biotech and Pharmaceutical Companies, Medical Device Companies, and Others), and Geography
Feb 2024
Antimicrobial Surgical Suture Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Triclosan Antimicrobial Suture and Chlorhexidine Antimicrobial Suture), Raw Materials (Polyglactin 910 Antimicrobial Suture, Poliglecaprone 25, and Polyglycolic Acid), Application (Cardiovascular Surgery, General Surgery, Ophthalmic Surgery, Gynecological Surgery, Orthopedic Surgery, Plastic Surgery, Veterinary Surgery, Dental Surgery, and Others), End User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Feb 2024
Organoids Services Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Intestine, Liver, Stomach, Pancreas, Lung, Brain, Kidney, and Others), Application (Developmental Biology Disease, Pathology of Infectious Disease, Regenerative Medicine, Drug Toxicity & Efficacy Testing, Drug Discovery & Personalized Medicine, and Others), Source (Pluripotent Stem Cells and Organ Specific Adult Stem Cell), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Feb 2024
Smart Hospital Beds Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Patient Weight (Less than 70 lb, 70 to 150 lb, 150 to 400 lb, 400 to 500 lb, Greater than 500 lb); Offering (Products and Accessories, Software and Solutions, and Services); Application (Fall Prevention, Pressure Injury Prevention, Patient Deterioration and Monitoring, and Others); End User (Hospitals, Clinics and Nursing Homes, Ambulatory Surgical Centers, Medical Laboratories, Long Term Care Centers, and Others), and Geography
Feb 2024
Infectious Disease Therapeutics Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class (Anti-viral, Anti Bacterial, Anti-Fungal, and Others), Indication (HIV, Hepatitis, Tuberculosis, Influenza, HPV, and Others), Route of Administration (Oral, Parenteral, Topical, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Geography
Get Free Sample For